Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 2/20 | 0.50 |
| ▸ | GRM6 | O15303 | 2/20 | 0.50 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9503510 | 0.93 | NAAA (0.47) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL1845737 | 0.91 | NAAA (0.49) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL18071166 | 0.91 | NAAA (0.49) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL3926151 | 0.86 | BLM (0.48) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL10935602 | 0.85 | NAAA (0.39) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL3450598 | 0.81 | GRIK1 (0.42) | SLC1A1GRIK1GRIA1GRIA2SLC1A3 | |
| SCHEMBL2162458 | 0.78 | SLC1A1 (0.60) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL29202853 | 0.77 | NAAA (0.49) | GRIN1GRIN2BNAAAALDH1A1TSHR | |
| SCHEMBL10932186 | 0.76 | SLC1A1 (0.62) | SLC1A1GSRGRM8GRM6GRM7 | |
| SCHEMBL19690548 | 0.75 | NAAA (0.52) | NAAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0135429-A1 | The synthesis of cyclopropane amino acids and peptides | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1985-03-27 | — | — | EP | claimed |
| WO-1985000809-A1 | THE SYNTHESIS OF CYCLOPROPANE AMINO ACIDS AND PEPTIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1985-02-28 | — | — | WO | claimed |
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1695961-A1 | UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20020168337-A1 | Sustained-release preparation | TAKADA CHEMICAL INDUSTRIES LTD. | 2002-11-14 | — | — | US | disclosed |
| US-20020058622-A1 | Sustained-release preparation | IGARI YASUTAKA (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6376461-B1 | WATER INSOLUBLE OR SLIGHTLY WATER SOLUBLE POLYVALENT METAL SALT OF A GROWTH HORMONE, AND A BIODEGRADABLE POLYMER; ENDOTHELIN ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-6147051-A | ANTIISCHEMIC AGENT | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| US-6087324-A | A WATER-INSOLUBLE OR A SLIGHTLY WATER-SOLUBLE POLYVALENT METAL SALT OF A WATER-SOLUBLE PHYSIOGICALLY ACTIVE PEPTIDE WHICH IS NOT AN ENDOTHELIN ANTAGONIST, AND A BIODEGRADABLE POLYMER SUCH AS COPOLYMER OF GLYCOLIC AND LACTIC ACID | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| EP-0552417-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-07 | — | — | EP | disclosed |
| US-5753619-A | CYCLIC HEPTAPEPTIDES FOR CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INSUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0528312-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-07-16 | — | — | EP | disclosed |
| US-5616684-A | CYCLIC HEXAPEPTIDE CONTAINING ASPARTIC ACID AND DERIVATIVES, 2-THIENYLGLYCINE, LEUCINE, AND TRYPTOPHAN; ENDOTHELIN RECEPTOR ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-01 | — | — | US | disclosed |
| EP-0714909-A1 | Composition for prophylaxis or treatment of pulmonary circulatory diseases | Takeda Chemical Industries, Ltd. (JP) | 1996-06-05 | — | — | EP | disclosed |
| CN-1109780-A | Sustained-release preparation of anti-endothelin substance | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-10-11 | — | — | CN | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020168337-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | SLC1A1 171/4885GSR 3785/4885GRM8 3096/4885 |
| US-20020058622-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | SLC1A1 171/4885GSR 3785/4885GRM8 3096/4885 |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | SLC1A1 3985/4885GSR 1009/4885GRM8 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.